Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Preventing new HIV infections remains a global challenge. Young women continue to bear a disproportionate burden of infection. Oral pre-exposure prophylaxis (PrEP), offers a novel women-initiated prevention technology and PrEP trials completed to date underscore the importance of their inclusion early in trials evaluating new HIV PrEP technologies. Data from completed topical and systemic PrEP trials highlight the role of gender specific physiological and social factors that impact PrEP uptake, adherence and efficacy. Here we review the past and current developments of HIV-1 prevention options for women with special focus on PrEP considering the diverse factors that can impact PrEP efficacy. Furthermore, we highlight the importance of inclusion of female scientists, clinicians, and community advocates in scientific efforts to further improve HIV prevention strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763292 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.1055042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Social Determinants of Health and HIV Diagnosis Rates in U.S. Counties, Comparing Ending the Epidemic (EHE) and Non-EHE Priority Jurisdictions.
AIDS Behav
September 2025
College of Nursing, University of South Florida, Tampa, FL, USA.
In the U.S., HIV diagnoses have remained steady over the past decade - despite the availability of condoms and pre-exposure prophylaxis.
View Article and Find Full Text PDFMeasurement and interpretation of the Harare HIV combination prevention cascade in priority populations: a population survey of adolescent girls and young women and young men in Zimbabwe.
BMJ Public Health
August 2025
MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Introduction: HIV-negative adolescent girls and young women (AGYW), and men (ABYM), have disproportionately high HIV incidence in many African countries. We used a new HIV Prevention Cascade (HPC) approach to quantify levels of, and barriers to, prevention method use to guide interventions to increase effective uptake of primary HIV prevention.
Methods: Data from the Manicaland HPC pilot study (2018-19; n=9803) in Zimbabwe were used to measure levels of sexual risk behaviour and construct HPCs for male condom, pre-exposure prophylaxis (females), voluntary medical male circumcision (males) and combination prevention use by HIV-negative sexually active AGYW (15-24 years) and male partners (15-29 years).
Venous Thromboembolism Risk Assessment in Prolonged Fasting During Ramadan: The Global Ramadan Free Thrombosis Project.
Cureus
August 2025
Vascular Surgery, University Hospitals of Leicester NHS Trust, Leicester, GBR.
Background Fasting during the month of Ramadan is practiced by over a billion Muslims worldwide. This religious observance, which involves complete abstention from food and fluids during daylight hours, may contribute to dehydration and increase the risk of venous thromboembolism (VTE), particularly in hot climates. Despite this theoretical concern, limited clinical evidence exists on the actual incidence and risk of VTE associated with prolonged fasting.
View Article and Find Full Text PDFHIV risk perception and associated factors among pregnant and breastfeeding women in Zambia: implications for PrEP uptake in antenatal and postnatal settings.
Front Reprod Health
August 2025
Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Introduction: HIV risk perception is seen as a key motivation for individuals to use biomedical HIV prevention interventions, including pre-exposure prophylaxis (PrEP). We determined HIV risk perception and associated factors among pregnant and breastfeeding women in Lusaka, Zambia.
Methodology: We conducted a cross sectional study among pregnant and breastfeeding women not living with HIV in a hospital setting in Lusaka, Zambia.
Nondisclosure of use of antiretroviral medications in Canadian blood donors.
Transfusion
September 2025
Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
Introduction: Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.
Methods: EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine.